UNSPSC 51183513: Phenformin hydrochloride

This classification denotes an anti-diabetic agent with the molecular formula C10H15N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91XC93EU03, chemically known as imidodicarbonimidic diamide, n- (2-phenylethyl)-, monohydrochloride but more generally known as phenformin hydrochloride, which bears US NIH Compound Identifier 8249. European Medicines Agency schedules Phenformin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03743MIG.

Most nations, for tariff and trade purposes, schedule phenformin hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, PHENFORMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phenformin hydrochloride bears US NLM identifiers UMLS ID C0770237 and NCI Concept Code C81696. SMILES: C1CCC(CC1)CCNC(=N)NC(=N)N.CL.

UNSPSC 51183513 Phenformin hydrochloride is a Commodity code covering the supply of a specific generic pharmaceutical product into state and local government health systems and facilities. State and local governments procure under this code when they stock and distribute phenformin hydrochloride — a biguanide antidiabetic agent — through their pharmaceutical supply chains, typically via cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and reduce unit costs. The issuing bodies soliciting under this code are state procurement offices and multistate cooperative purchasing alliances that serve state agencies, local health departments, correctional facilities, and public hospital systems. A single large-scale cooperative procurement can establish framework agreements that span multiple states and hundreds of public facilities at once.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including phenformin hydrochloride, for distribution across participating state and local government facilities in Minnesota and Oregon. The procurement requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and mandates cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with at least two of the three wholesalers with chargeback systems in place. The contract runs two years for new responders with optional extensions, becoming effective July 1, 2026, and evaluation is weighted 75 percent on price competitiveness, 10 percent on fixed pricing compliance, and 5 percent each on administrative-fee-data-format compliance, EDI capability, and agreement to a 3 percent administrative fee. Proposals required submission through the ePro system in designated Excel/CSV format by March 26, 2026, with a questions cutoff of February 18, 2026.